Recently in ASCO Annual meeting, a multicenter real‐world data of adjuvant treatment from German with 288 Stage III BRAF‐mutant melanoma patients identified, also showed that risk of recurrence was higher and earlier for immunotherapy than for targeted therapy.15 Here, BRAF is linked to melanoma.